These four top dividend stocks offer dependable passive income streams and solid total return, and they are too cheap to ...

Here are three dividend stocks that retirees can buy with confidence as they offer recurring, dependable payouts and a degree ...

Earlier patent litigation can be reformed to reflect similar success across Europe, resulting in accelerated US biosimilar ...

Dividend stocks are a favorite among investors for good reason. They provide a steady income stream of passive income and ...

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the ...

Organon has faced significant price volatility and underperformance since its spin-off from Merck. Check out why I recommend ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...

(RTTNews) - Sandoz Group AG (SDZNY), a Swiss generic and biosimilar medicines maker, Tuesday announced that the global generics and biosimilars market, which is worth more than $200 billion in ...

Amgen's biosimilar ambition is targeting several ... especially while its shares remain down. Pfizer's dividend is safer than it looks David Jagielski(Pfizer): A high-yielding stock that could ...

Pfizer's dividend is safer than it might seem ... Now, though, Humira's sales are falling as it faces biosimilar competition. The good news is that AbbVie has prepared well for this scenario.

Three Motley Fool contributors have identified some especially great high-yield dividend stocks to buy in 2025 -- and all of them are big pharma stocks. Here's why they chose AbbVie(NYSE: ABBV), Amgen ...